B+
Bull case
20%
Probability
Target price
$38.00
Analysis reference price unavailable
Analysis 2026-09-12 · RankAlpha Sentiment Codex
TCMD
TactileBNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
Healthy lymphedema growth, gross-margin expansion, higher adjusted EBITDA, approximately $70 million of quarter-end cash, and a broader product portfolio could produce operating leverage if AffloVest ordering normalizes. [#SEC-8K-2026-08-10] [#PR-EARNINGS-2026-08-18]
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -17.2.
What can break
A CEO open-market sale of 10,978 shares for approximately $323,243 occurred on August 10; the filing does not establish any operating implication. [#SEC-FORM4-2026-08-12]
Momentum
4
Value
63
Sentiment
73
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $26.00 · Bull $38.00 · Bear $17.00Analysis 2026-09-12; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-11 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-12 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-11
Investment thesis
As of 2026-09-11
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-11. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $39.00
Why
Momentum4 · Δ7d +0.4
Value63 · Δ7d -0.0
Sentiment73 · Δ7d -17.2
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -17.2.
Contradictions & invalidation
- • A CEO open-market sale of 10,978 shares for approximately $323,243 occurred on August 10; the filing does not establish any operating implication. [#SEC-FORM4-2026-08-12]
- • AffloVest inventory management at several large DME partners may persist longer than anticipated, delaying airway-clearance recovery. [#SEC-8K-2026-08-10]
- • Airway-clearance revenue declined during the AffloVest transition, and management adopted a more conservative view of DME ordering patterns.
Catalyst clock
2026-08-10
Q2 growth and profitability expansion
Lead driver: Sentiment · See AI snapshot
Momentum
4
9% active weight
Current posture
7d trendFlat
Δ7d
+0.4
Δ21d
-7.9
Value
63
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+1.6
Sentiment
73
62% active weight
Current posture
7d trendSoftening
Δ7d
-17.2
Δ21d
-2.1
Why this grade
Composite grade B. Momentum 3.9 / Value 63.0 / Sentiment 72.7
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-12. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$26.00
Analysis reference price unavailable
Analysis 2026-09-12 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$17.00
Analysis reference price unavailable
Analysis 2026-09-12 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$557.02M
Beta
0.96
Shares Out
22.65M
P/E (TTM)
38.8
P/S (TTM)
2.16
P/FCF (TTM)
17.08
Rev YoY
+8.6%
EPS YoY
+143.9%
Gross Margin
+76.1%
Op Margin
+10.0%
Net Debt
-$67.49M
Current Ratio
4.12
As of 2026-09-11 • Updated nightlySource: Internal modelMethods & Data